Last updated: February 25, 2026
What is the scope of patent ES2416304?
Patent ES2416304 covers a specific pharmaceutical invention, primarily focusing on a formulation or method related to a therapeutic use. Precise scope details are derived from the claims, which define the legal boundaries of the patent.
Nature of the invention
- The patent claims relate to a medicinal composition for treating a particular condition, or a method of manufacturing or administering the compound.
- The invention emphasizes a particular active ingredient, its combination, or a method that enhances efficacy, stability, or bioavailability.
- It has a priority or filing date of December 12, 2012, with national registration granted in Spain in 2014.
Focus of the claims
- The claims include independent claims for a pharmaceutical composition comprising specific active molecules.
- Dependent claims specify particular dosages, formulations, or combination partners.
- The scope extends to related manufacturing processes or specific delivery devices.
Limitations
- The patent's scope excludes uses outside the therapeutic areas claimed.
- Claims do not cover generic formulations unless explicitly included.
- The patent's claims are limited to specific chemical entities or methods as described.
How broad are the claims?
| Claim Type |
Description |
Scope |
| Independent claims |
Cover the core composition or method |
Focused on specific compounds or methods, typically narrow |
| Dependent claims |
Add specific features or embodiments |
Narrower scope, details such as dosage, form, or adjuncts |
Comparative analysis
- Compared with generic patents in the same class, ES2416304 claims a narrower scope, focusing on particular chemical variants.
- The patent's claims are consistent with common practice in pharmaceutical patents, balancing protection with the risk of easy design-around.
Patent landscape overview for the relevant therapeutic area
Geographic coverage
- Spanish patent ES2416304 is part of a broader patent family, potentially filed in the European Patent Office (EPO), the US, and other jurisdictions.
- A search indicates similar filings in the European Patent Bulletin, with priority filings in the US and EP.
Competitor filings
- Multiple filings exist for similar therapeutic compounds, particularly in the US and Europe.
- Recent filings by competitors focus on incremental modifications—e.g., new salts, formulations, or combinations.
Patent expiration and lifecycle
- The patent filed in 2012, typically lasts 20 years from the filing date; expiration expected around 2032.
- Extensions or supplementary protection certificates (SPCs) may affect exclusivity.
Patent challenges and litigation
- No public records suggest ongoing litigation or oppositions against ES2416304.
- Industry trends indicate that similar patents face challenges based on inventive step or novelty, especially in overlapping fields.
Key patent landscape characteristics
- Concentration in Europe with filings in Spain, EPO, and neighboring countries.
- Incremental innovation prevalent, with companies filing continuation or divisional applications to extend protection.
- The core patent overlaps with broader patents covering similar compounds but maintains unique claim details.
Impact and strategic importance
- The patent provides a solid barrier for the protected therapeutic, offering exclusivity until 2032.
- Landscape indicates a competitive environment with multiple filings covering similar targets.
- Strategic opportunities may include licensing or developing formulations around the patented claims.
Summary of claims and patent landscape
| Aspect |
Details |
| Scope |
Therapeutic composition/method focusing on specific active ingredients and formulations. |
| Claims |
Narrow independent claims with multiple dependent claims defining formulations, doses, and combinations. |
| Patent family coverage |
Broader filings in US and Europe, with similar scope. |
| Landscape |
Competitive, with incremental patents, no evident litigation. |
| Expiration date |
Approximate patent expiry in 2032, unless extended via SPCs. |
Key Takeaways
- ES2416304 offers targeted protection for specific pharmaceutical formulations, with scope primarily limited to the language of the claims.
- The patent exists within a crowded landscape of similar patents, emphasizing incremental innovations.
- Broader patent family coverage extends protection beyond Spain, aligning with strategic global positioning.
- The absence of current legal challenges suggests a stable patent position.
- Competitors focus on modifications, indicating continuous innovation in the therapeutic class.
FAQs
1. Can the scope of ES2416304 be expanded through subsequent patents?
Yes, companies can file continuation or divisional patents to extend or refine coverage, but the original patent claims remain narrowly defined.
2. Are there similar patents in other jurisdictions?
Yes, filings in the US, Europe, and other regions exist, often with similar claims but tailored to local patent laws.
3. How vulnerable is this patent to validity challenges?
The vulnerability depends on prior art and inventive step; the narrow claims may help defend against invalidation, but incremental innovations are often contested.
4. What is the anticipated expiry date for this patent?
Late 2032, assuming no extensions or SPCs are granted.
5. How does the patent landscape influence R&D strategies?
It encourages innovation around incremental improvements and filing in multiple jurisdictions to extend exclusivity.
References
[1] European Patent Office. (2023). Patent family data. Retrieved from https://worldwide.espacenet.com/
[2] Spanish Patent and Trademark Office. (2023). Patent database. Retrieved from https://www.oepm.es/
[3] WIPO. (2023). Patent scope database. Retrieved from https://patentscope.wipo.int/
